Analyst Ratings For Viveve Medical (NASDAQ:VIVE)
Today, Maxim Group reiterated its Buy rating on Viveve Medical (NASDAQ:VIVE) with a price target of $11.00.
Some recent analyst ratings include
- 3/16/2018-Maxim Group Reiterated Rating of Buy.
- 2/8/2018-Mizuho Reiterated Rating of Buy.
- 1/4/2018-Ladenburg Thalmann Financial Services Reiterated Rating of Buy.
- 1/5/2018-Northland Securities initiated coverage with a Outperform rating.
- 5/25/2017-Raymond James Financial initiated coverage with a Outperform rating.
- 5/17/2017-B. Riley Reiterated Rating of Buy.
Recent Insider Trading Activity For Viveve Medical (NASDAQ:VIVE)
Viveve Medical (NASDAQ:VIVE) has insider ownership of 35.10% and institutional ownership of 40.60%.
- On 8/23/2017 Scott Durbin, CFO, bought 5,000 with an average share price of $5.25 per share and the total transaction amounting to $26,250.00.
- On 3/17/2017 James G Atkinson, Director, bought 375,000 with an average share price of $4.00 per share and the total transaction amounting to $1,500,000.00.
- On 3/17/2017 Patricia Scheller, CEO, bought 12,500 with an average share price of $4.00 per share and the total transaction amounting to $50,000.00.
- On 6/17/2016 James G. Atkinson, Insider, bought 100,000 with an average share price of $5.00 per share and the total transaction amounting to $500,000.00.
- On 6/17/2016 Patricia Scheller, CEO, bought 6,000 with an average share price of $5.00 per share and the total transaction amounting to $30,000.00.
- On 6/17/2016 Scott Durbin, CFO, bought 1,500 with an average share price of $5.00 per share and the total transaction amounting to $7,500.00.
- On 6/17/2016 Stonepine Capital Management,, Major Shareholder, bought 300,000 with an average share price of $5.00 per share and the total transaction amounting to $1,500,000.00.
Recent Trading Activity for Viveve Medical (NASDAQ:VIVE)
Shares of Viveve Medical closed the previous trading session at 4.08 down -0.03 0.73% with 39207 shares trading hands.